Treatment focuses on preventing additional ... This deficiency affects the GCase enzyme and increases a patient's risk of ...

The new 'living' guideline marks a major shift away from the traditional step-up approach, recommending early use of advanced therapies such as biologics and small molecules after 5-aminosalicylic ...

Patients with skin disease adhering to a proper diet may experience better treatment responses and a reduced risk of adverse ...

Conclusion: A patient with HIT developed severe skin necrosis after initiation of warfarin therapy. Warfarin is an integral component of heparin-induced thrombocytopenia (HIT) treatment.

Aura Biosciences (AURA) announced data from a completed Phase 1 window of opportunity trial of bel-sar in patients with NMIBC. These data were ...

In April 2008, certolizumab pegol (Cimzia; UCB), a tumour-necrosis factor blocker, was approved by the US FDA for the treatment of adult patients with moderate-to-severe Crohn's disease who have ...

Teclison is a clinical stage oncology company advancing an immunotherapy treatment for solid tumors utilizing a three-pronged approach that: (1) induces tumor necrosis; (2) expands anti-tumor T cells ...

Tharimmune, Inc. (Nasdaq:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its ...

A University of Pennsylvania research team has shown that it can kill tumor cells in mice by necrosis, rather than by inducing apoptosis, by giving them alkylating agents that block their energy ...